Summary
Gilead Sciences, Inc. (GILD) announced a key leadership change in its financial reporting structure through an 8-K filing on August 13, 2025. The company has appointed Erin Burkhart as the new Senior Vice President, Controllership and principal accounting officer, effective September 22, 2025. This appointment brings a seasoned financial executive with extensive experience in the biotechnology and pharmaceutical sectors to a critical role within Gilead's finance organization. Ms. Burkhart's prior roles include Group Vice President and Chief Accounting Officer at BioMarin Pharmaceutical Inc., and various senior accounting and finance positions at Eli Lilly and Company. Her background in public accounting with major firms and her CPA certification underscore her qualifications for overseeing Gilead's financial reporting. This transition marks a change in leadership for the principal accounting officer role, with Diane E. Wilfong stepping down from her interim position.
Key Highlights
- 1Gilead Sciences (GILD) appointed Erin Burkhart as Senior Vice President, Controllership and principal accounting officer.
- 2The appointment is effective September 22, 2025.
- 3Ms. Burkhart brings significant experience from BioMarin Pharmaceutical Inc. where she served as Group Vice President and Chief Accounting Officer.
- 4Her previous tenure includes roles of increasing responsibility in accounting and finance at Eli Lilly and Company.
- 5Ms. Burkhart is a licensed certified public accountant (CPA) with a strong foundation in public accounting.
- 6Diane E. Wilfong will step down from her interim role as Controller and principal accounting officer.
- 7This executive appointment is a material event disclosed via an 8-K filing.